...
search icon
vnda-img

Vanda Pharmaceuticals Inc, Common Stock

VNDA

NMQ

$4.47

-$0.04

(-0.89%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$269.92M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
259.49K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.67
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.81 L
$6.37 H
$4.47

About Vanda Pharmaceuticals Inc, Common Stock

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameVNDASectorS&P500
1-Week Return-2.4%-2.62%-1.15%
1-Month Return3.23%1.4%2.88%
3-Month Return-7.26%-10.19%3.46%
6-Month Return-4.49%-4.75%0.1%
1-Year Return-25.25%-10.15%9.45%
3-Year Return-58.5%3.99%56.88%
5-Year Return-62.41%31.67%90.07%
10-Year Return-65.36%72.87%181.73%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue248.17M268.68M254.38M192.64M198.77M[{"date":"2020-12-31","value":92.36,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":94.68,"profit":true},{"date":"2023-12-31","value":71.7,"profit":true},{"date":"2024-12-31","value":73.98,"profit":true}]
Cost of Revenue23.36M25.63M24.28M17.57M11.31M[{"date":"2020-12-31","value":91.16,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":94.74,"profit":true},{"date":"2023-12-31","value":68.57,"profit":true},{"date":"2024-12-31","value":44.15,"profit":true}]
Gross Profit224.80M243.05M230.10M192.64M187.46M[{"date":"2020-12-31","value":92.49,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":94.67,"profit":true},{"date":"2023-12-31","value":79.26,"profit":true},{"date":"2024-12-31","value":77.13,"profit":true}]
Gross Margin90.59%90.46%90.45%100.00%94.31%[{"date":"2020-12-31","value":90.59,"profit":true},{"date":"2021-12-31","value":90.46,"profit":true},{"date":"2022-12-31","value":90.45,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":94.31,"profit":true}]
Operating Expenses197.56M200.89M223.77M206.59M228.12M[{"date":"2020-12-31","value":86.61,"profit":true},{"date":"2021-12-31","value":88.06,"profit":true},{"date":"2022-12-31","value":98.09,"profit":true},{"date":"2023-12-31","value":90.56,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income27.24M42.16M6.33M(13.95M)(40.66M)[{"date":"2020-12-31","value":64.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":15.01,"profit":true},{"date":"2023-12-31","value":-33.09,"profit":false},{"date":"2024-12-31","value":-96.43,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income31.66M42.36M11.30M6.34M(22.92M)[{"date":"2020-12-31","value":74.72,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":26.67,"profit":true},{"date":"2023-12-31","value":14.96,"profit":true},{"date":"2024-12-31","value":-54.1,"profit":false}]
Income Taxes8.32M9.21M5.03M3.83M(4.02M)[{"date":"2020-12-31","value":90.3,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":54.55,"profit":true},{"date":"2023-12-31","value":41.58,"profit":true},{"date":"2024-12-31","value":-43.65,"profit":false}]
Income After Taxes-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations23.34M33.15M6.28M11.77M(18.90M)[{"date":"2020-12-31","value":70.39,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":18.93,"profit":true},{"date":"2023-12-31","value":35.5,"profit":true},{"date":"2024-12-31","value":-57.01,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income23.34M33.15M6.28M2.51M(18.90M)[{"date":"2020-12-31","value":70.39,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":18.93,"profit":true},{"date":"2023-12-31","value":7.57,"profit":true},{"date":"2024-12-31","value":-57.01,"profit":false}]
EPS (Diluted)0.430.580.120.05(0.33)[{"date":"2020-12-31","value":74.14,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":20.69,"profit":true},{"date":"2023-12-31","value":9.03,"profit":true},{"date":"2024-12-31","value":-56.21,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VNDA
Cash Ratio 3.28
Current Ratio 3.93
Quick Ratio 3.91

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VNDA
ROA (LTM) -7.05%
ROE (LTM) -8.39%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VNDA
Debt Ratio Lower is generally better. Negative is bad. 0.19
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.81

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VNDA
Trailing PE NM
Forward PE 30.30
P/S (TTM) 1.32
P/B 0.52
Price/FCF NM
EV/R 0.59
EV/Ebitda 12.91
PEG NM

FAQs

What is Vanda Pharmaceuticals Inc share price today?

Vanda Pharmaceuticals Inc (VNDA) share price today is $4.47

Can Indians buy Vanda Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Vanda Pharmaceuticals Inc (VNDA) on Vested. To buy Vanda Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VNDA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Vanda Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Vanda Pharmaceuticals Inc (VNDA) via the Vested app. You can start investing in Vanda Pharmaceuticals Inc (VNDA) with a minimum investment of $1.

How to invest in Vanda Pharmaceuticals Inc shares from India?

You can invest in shares of Vanda Pharmaceuticals Inc (VNDA) via Vested in three simple steps:

  • Click on Sign Up or Invest in VNDA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Vanda Pharmaceuticals Inc shares
What is Vanda Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Vanda Pharmaceuticals Inc (VNDA) is $6.37. The 52-week low price of Vanda Pharmaceuticals Inc (VNDA) is $3.81.

What is Vanda Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Vanda Pharmaceuticals Inc (VNDA) is 0.52

What is the Market Cap of Vanda Pharmaceuticals Inc?

The market capitalization of Vanda Pharmaceuticals Inc (VNDA) is $269.92M

What is Vanda Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Vanda Pharmaceuticals Inc is VNDA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top